VLON Vallon Pharmaceuticals

Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit

Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit

Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET

PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, announced today that of Vallon will present at the on Tuesday, May 18th at 4:15 PM ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the .

A live of the presentation will be accessible on the page in the section of the Company’s website () and will be archived for 90 days following the event.

About Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

For more information about the company, please visit .

References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vallon is not responsible for the contents of third-party websites.

Investor Contact:

JTC Team, LLC

Jenene Thomas

(833) 475-8247



EN
07/05/2021

Underlying

VLONVallon Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vallon Pharmaceuticals

 PRESS RELEASE
Free
VLON Vallon Pharmace...

Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.

Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc. Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T (“NKT”) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseasesInvestment proceeds expected to fund planned operations of the combined company into mid-2024 Trading on Nasdaq under the ticker symbol “GRI” expected to commence April 24, 2023 PHILADELPHIA, PA, April 21, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: VLON), (“GRI,” “GRI Bio,” or the “Company”), today announced the completion of the pr...

April 21, 2023 1 EN
 PRESS RELEASE
Free
VLON Vallon Pharmace...

Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until ...

Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023 Board of Directors unanimously recommend Vallon stockholders to vote “FOR” all proposals outlined in the Company’s definitive Proxy Statement (the “Proxy”) in order to close the proposed merger with GRI Bio, Inc. PHILADELPHIA, PA, April 12, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today announced that its Special Meeting of Stockholders, scheduled for and convened on April 12, 2023, has been adjourned to provide the Company’s stockholders addi...

April 12, 2023 1 EN
 PRESS RELEASE
Free
VLON Vallon Pharmace...

Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Prop...

Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ET Over 90% of the shares voted to date have shown support “FOR” each of the five proposals, but additional votes are needed in order to close the proposed merger with GRI Bio PHILADELPHIA, PA, April 04, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today urges its stockholders of record as of March 6, 2023 to vote in favor of all of the proposal...

April 4, 2023 1 EN
 PRESS RELEASE
Free
VLON Vallon Pharmace...

Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results

Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December 31, 2022. In December 2022, Vallon announced it had entered into a definitive agreement (the “Merger Agreement”) with GRI Bio, Inc. (“GRI Bio”), a privately held biotechnology company with the goal of advancing an innovative pipeline of Natural Killer T (“NKT”) cell regulators for the treatment of inflammatory, fibrotic and ...

February 24, 2023 1 EN
 PRESS RELEASE
Free
VLON Vallon Pharmace...

Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor ...

Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event Live video webcast on Tuesday, January 17, 2023 at 1:00 PM ET PHILADELPHIA, PA and LA JOLLA, CA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), and GRI Bio, Inc. (“GRI Bio”), a privately held biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that David Baker, President & Chief Executive Officer of ...

January 11, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch